Clinical trial
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals'…
NCT00320463 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00320463 |
|---|---|
| Title | Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants |
| Official title | Compare Immunogenicity & Reactogenicity of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine (New vs Current) Given in Healthy Infants. The DTPa-HBV-IPV Vaccine (New Formulation) Will Also be Assessed in a 3rd Group of Subjects |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Hepatitis B, Poliomyelitis, Tetanus, Acellular Pertussis |
| Intervention type | Biological |
| Interventions | DTPa-HBV-IPV/Hib vaccine |
| Enrollment | 415 |
| Start date | Apr 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | May 3, 2006 |
| Last update posted | Oct 12, 2016 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: